Valeant Pharmaceuticals: All That Deal Making Pays Off?

Valeant Pharmaceuticals (VRX) is know for being acquisition hungry. All that deal making has paid off, at least according to second-quarter financial results. At $248.44, the shares spiked 4.6% in recent trading after earlier rising as high as $249.92 after the drug maker boosted its full-year financial forecasts for 2015 on the heels of better-than-expected [...]
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.